Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript

ARENA PHARMACEUTICALS INC (ARNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/11/2022 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Arena Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Arena Pharmaceuticals, Inc"
03/10/2022 8-K Other Events  Interactive Data
02/23/2022 8-K Quarterly results
Docs: "Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates –Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout"
02/07/2022 8-K Quarterly results
02/02/2022 8-K Quarterly results
01/07/2022 8-K Other Events  Interactive Data
12/13/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Arena Reports Third Quarter Financial Results and Key Program Updates –Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout"
08/05/2021 8-K Quarterly results
Docs: "Arena Reports Second Quarter Financial Results and Key Program Updates –Phase 3 ELEVATE UC 12 trial reached full enrollment&#59; topline data expected Q1 2022 with ELEVATE UC 52"
06/17/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/18/2020 8-K Investor presentation
Docs: "Arena Pharmaceuticals corporate slide presentation dated November 2020"
11/09/2020 8-K Quarterly results
Docs: "Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis"
10/28/2020 8-K Asset disposition
10/26/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation titled “Atopic Dermatitis Overview,” dated October 2020"
09/23/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
06/16/2020 8-K Appointed a new director
Docs: "Certificate of Amendment No. 5 of the Fifth Amended and Restated Certificate of Incorporation of Arena, as amended",
"Amended and Restated Bylaws of Arena"
06/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/28/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Arena Pharmaceuticals, BofA Securities, Inc., Citigroup Global Markets Inc. and SVB Leerink LLC, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock",
"Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock"
05/27/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/07/2020 8-K Quarterly results
04/01/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arena Pharmaceuticals Announces Positive Topline Data for New Development Program -Etrasimod Controlled-Release - Etrasimod CR profile designed to retain etrasimod’s rapid onset of action while further improving its potentially best-in-class, non-titrated, low intrinsic first-dose heart rate effect"
02/26/2020 8-K Quarterly results
01/13/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2020 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "- EXCERPT OF CONFERENCE CALL TRANSCRIPT"
11/07/2019 8-K Quarterly results
Docs: "Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs"
08/07/2019 8-K Quarterly results
Docs: "Pressrelease issued August 7, 2019, reporting financial results forthe second quarter ended June 30, 2019"
06/14/2019 8-K Appointed a new director
05/08/2019 8-K Quarterly results
Docs: "Pressrelease issued May 8, 2019, reporting financial results forthe first quarter ended March 31, 2019"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy